Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumors
Crossref DOI link: https://doi.org/10.1007/s00280-014-2486-9
Published Online: 2014-06-01
Published Print: 2014-08
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Plummer, Ruth
Stephens, Peter
Aissat-Daudigny, Louiza
Cambois, Anne
Moachon, Gilbert
Brown, Peter D.
Campone, Mario
License valid from 2014-06-01